Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A Georgetown University professor published in the online journal PLOS ONE the first study explaining why drugs designed to fight off malaria stop working in some people with the disease.
Malaria, a mosquito-borne disease caused by a parasite, killed more than 650,000 people in 2010 - most of them children in Africa, according to the World Health Organization.
While several antimalarial drugs have successfully treated the disease, in some regions they no longer work due to drug resistance. Given that just last month the CDC reported that malaria cases in the U.S. reached a 40-year high, this research is particularly timely.
A Global Threat
"Resistance to antimalarial medication threatens the health of more than half of the world's population," notes corresponding Paul Roepe, PhD, a Georgetown chemistry professor who authored the study with colleagues at the University of Notre Dame and the University of Kentucky.
Many antimalarial drugs both slow the growth of malarial parasites, and, at higher doses or over longer periods of time, also kill the malarial parasites.
"Until now, no studies have separated how resistance to these two different drug actions might work," says Roepe, also a professor of biochemistry and cell and molecular biology and co-founder of Georgetown's Center for Infectious Disease at Georgetown University Medical Center. "Our study found genetic and cell biological evidence linking autophagy to resistance to the parasite, which kills the effects of drugs."
Autophagy, Roepe explains, is the process by which cells remove damaged parts of themselves to restore normal function. In this case, the cell rids itself of the parts damaged by the antimalarial drug. Roepe worked with two alumni of the chemistry Ph.D. program, David Gaviria (G'13) and Michelle Paguio (G'09), as well as current student Ph.D. chemistry student Amila Siriwardana (G'16) on the research.
The professor and his colleagues demonstrated in their study that while resistance to drugs like chloroquine, which works to slow the growth of malaria, has been explored, an explanation of the resistance to the cell-destroying effects of the medication has not been fully understood.
"These results have important implications in the ongoing development of new antimalarial drug therapy," Roepe says. "We hope that by publishing this work in an open access journal, more researchers will access it and can expedite drug development.
This research was supported by grants from the National Institutes of Health (RO1 AI045957, RO1AI49367, RO1 AI071121) and by a Kentucky Science and Engineering Foundation award. The authors declare no conflict of interest.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Tropical Diseases category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Georgetown University Medical Center. "Type of antimalarial drug resistance explained." Medical News Today. MediLexicon, Intl., 22 Nov. 2013. Web.
21 Apr. 2014. <http://www.medicalnewstoday.com/releases/269161>
Georgetown University Medical Center. (2013, November 22). "Type of antimalarial drug resistance explained." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/269161.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.